India's Glenmark to conduct trials for potential COVID-19 drug, shares jump
Reuters: Health
Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.
Subscribe to:
Post Comments (Atom)
Subscribe UsPopular Posts
|
No comments:
Post a Comment